Abstract
We report the biochemical characterization, replication, and preclinical trial of a melanin-integrated hemoprotein analogue (“MHA-1”), reverse-engineered from tissue and notation samples recovered under UNSF evidentiary custody following the 2105 Artemis base incident. MHA-1 incorporates a melanin-derived pigment structure covalently integrated into a modified hemoprotein scaffold, conferring measurable radioprotective capacity through non-enzymatic dissipation of ionizing radiation as chemical energy, alongside oxygen transport efficiency exceeding unmodified baseline hemoglobin by a modest but consistent margin. Murine trials (n=340, 2118–2120) demonstrated significantly reduced radiation-induced cellular damage under controlled dosimetric exposure relative to unmodified controls, with no observed adverse hematological, hepatic, or renal effects across a 14-month observation window. Subsequent trials in Pan troglodytes (n=12, 2120–2121) replicated both radioprotective and oxygen-transport findings with comparable safety profile. Human Phase I trials are scheduled for 2124 pending final institutional review. We additionally report preliminary pharmacological findings on skeletal density preservation derived from the same recovered material, with substantial technical limitations discussed below.
1. Provenance and Ethical Statement
The substrate material underlying this research was recovered by United Nations Security Force personnel during the 2105 raid on an Artemis base facility occupied by the extremist group Dominium Hominis, and was held under evidentiary custody until 2109, when limited research access was granted to Luna Research Dome 4 under UN Office for Emerging Technology Governance oversight. The original material derives from non-consensual and, in multiple documented cases, fatal self-experimentation and experimentation on minors, conducted entirely outside any recognized ethical or regulatory framework. No original human subjects associated with this material were, at any point, research participants of Dome 4 or any affiliated institution; no living original subjects were involved in this study. All animal trials described in this paper were conducted under standard UN Life Sciences ethical review, independent of and subsequent to the recovery of the original material. We include this statement as a condition of publication, per Dome 4 institutional policy, rather than as a footnote, and direct readers to the accompanying institutional statement on research provenance for further detail.
2. Background
Radioprotective pharmacology in extended EVA and deep-space contexts has, to date, relied primarily on compound-based approaches — most notably the SVR-class agents developed under the Gamaleya Centre’s Svarog program (Bondarenko et al., 2061–2074), which extend safe EVA rotation through metabolic and cellular-repair mechanisms without altering baseline radiation exposure tolerance. The Svarog program’s own findings were explicit that such approaches “buy time” rather than resolve underlying exposure risk. MHA-1 represents a structurally distinct approach: rather than mitigating radiation damage after exposure, the melanized hemoprotein structure appears to convert a measurable fraction of incident ionizing radiation into dissipated chemical energy at the point of interaction, a mechanism analogous to radiosynthetic processes documented in melanized fungal organisms recovered from high-radiation terrestrial environments. This is, to our knowledge, the first demonstration of this mechanism integrated into a functional mammalian oxygen-transport protein.
3. Methods
Substrate biochemical sequences were reconstructed from recovered tissue samples and laboratory notation using standard sequence-recovery protocol; recovered material was independently verified against reconstructed synthesis pathways prior to any animal application. Murine subjects (C57BL/6, n=340) received MHA-1 substitution via standard hematopoietic protocol, followed by controlled dosimetric radiation exposure at graduated intervals over a 14-month observation period, with cellular damage markers assessed via standard histopathological and genomic-instability panels against unmodified littermate controls. Non-human primate trials (Pan troglodytes, n=12) followed comparable protocol under extended observation, with additional behavioral and cognitive-function monitoring given the closer physiological relevance to eventual human application.
4. Results
MHA-1-modified subjects across both trial populations showed statistically significant reduction in radiation-induced cellular damage markers relative to controls (p<0.01 in murine trials; primate trial sample size precludes equivalent statistical power but shows consistent directional effect). Oxygen transport efficiency, measured via standard saturation and delivery-rate assay, exceeded unmodified baseline by 6–9% across both populations. No adverse hematological, hepatic, or renal findings were observed in either trial population across the full observation window. No behavioral or cognitive abnormalities were observed in primate subjects.
5. Discussion and Limitations
These findings support MHA-1 as a viable candidate for progression to human Phase I trial, currently scheduled for 2124. We note explicitly that the radioprotective margin demonstrated, while significant, does not eliminate radiation risk and should not be characterized to future trial participants or the public as doing so; framing consistent with the Svarog program’s own historical caution is appropriate here.
We additionally report preliminary findings from a parallel line of recovered substrate material addressing skeletal density modification, observed in Dominium Hominis subjects as apparent congenital skeletal restructuring. Attempts to replicate density-enhancing effects in adult murine and primate subjects were unsuccessful; available evidence indicates the original modification was applied gestationally, prior to skeletal development onset, a route this division will not pursue in any subject regardless of application, per institutional ethical policy. A pharmacological derivative, administered post-natally, demonstrated a measurable reduction in the rate of bone density loss under simulated microgravity condition, though without the structural enhancement observed in the original subject population. This derivative is presented as a complementary intervention alongside existing countermeasures such as sustained-gravity rotational therapy, rather than a replacement for them, and is discussed in a forthcoming companion publication.
Funding and Institutional Disclosure
This research was conducted under UN Office for Emerging Technology Governance oversight at Luna Research Dome 4, with material access granted under evidentiary research exemption. The authors declare no competing financial interests.